Evidence map›Paper›PMID 36328790›Full record

ArticleAdvanced biology2023

Temporal Dynamics of Metabolic Acquisition in Grafted Engineered Human Liver Tissue.

Chelsea L Fortin, Tara N McCray, Sarah H Saxton, Fredrik Johansson, Christian B Andino, Jonathan Mene, Yuliang Wang, Kelly R Stevens

Open access · hybridAbstract read
In one paragraph

Article in Advanced biology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.3field-weighted citation impact, top 44% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
  3. A Systematic Review on Artificial Liver for Implantation.Journal of functional biomaterials · 2026
    Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Chelsea L FortinInstitute for Stem Cell & Regenerative Medicine, University of Washington, Seattle, Washington, 98109, USA.ORCID 0000-0002-6931-0862
Tara N McCrayInstitute for Stem Cell & Regenerative Medicine, University of Washington, Seattle, Washington, 98109, USA.ORCID 0000-0001-9034-7240
Sarah H SaxtonInstitute for Stem Cell & Regenerative Medicine, University of Washington, Seattle, Washington, 98109, USA.
Fredrik JohanssonInstitute for Stem Cell & Regenerative Medicine, University of Washington, Seattle, Washington, 98109, USA.ORCID 0000-0002-2411-0031
Christian B AndinoInstitute for Stem Cell & Regenerative Medicine, University of Washington, Seattle, Washington, 98109, USA.
Jonathan MeneInstitute for Stem Cell & Regenerative Medicine, University of Washington, Seattle, Washington, 98109, USA.
Yuliang WangInstitute for Stem Cell & Regenerative Medicine, University of Washington, Seattle, Washington, 98109, USA.
Kelly R StevensInstitute for Stem Cell & Regenerative Medicine, University of Washington, Seattle, Washington, 98109, USA.ORCID 0000-0002-4024-2990
California Institute for Regenerative Medicine · US

Funding

Environmetal Pathology/Toxicology Training ProgramT32ES007032 · NIEHS · UNIVERSITY OF WASHINGTON · PI FAUSTMAN, ELAINE M, ROSENFELD, MICHAEL E · 1985 to 2023
$10.7M
NRSA Training CoreTL1TR002318 · NCATS · UNIVERSITY OF WASHINGTON · PI Megan Moore · 2017 to 2026
$8.4M
Bioengineering Cardiovascular Training GrantT32EB001650 · NIBIB · UNIVERSITY OF WASHINGTON · PI REGNIER, MICHAEL · 2004 to 2019
$3.6M
Photoabsorbing bioinks for expanding 3D printed human liver in situR01DK128551 · NIDDK · UNIVERSITY OF WASHINGTON · PI STEVENS, KELLY R · 2021 to 2024
$3.0M
Molecular Medicine Training ProgramT32GM095421 · NIGMS · UNIVERSITY OF WASHINGTON · PI HAWN, THOMAS R, LILES, W. CONRAD · 2011 to 2020
$1.6M
NCATS NIH HHS TL1 TR002318NIBIB NIH HHS T32 EB001650NIDDK NIH HHS R01 DK128551NIEHS NIH HHS T32 ES007032NIGMS NIH HHS T32 GM095421NIH HHS R01DK128551
6 · The paper itself

Abstract

Liver disease affects millions globally, and end-stage liver failure is only cured by organ transplant. Unfortunately, there is a growing shortage of donor organs as well as inequitable access to transplants across populations. Engineered liver tissue grafts that supplement or replace native organ function can address this challenge. While engineered liver tissues have been successfully engrafted previously, the extent to which these tissues express human liver metabolic genes and proteins remains unknown. Here, it is built engineered human liver tissues and characterized their engraftment, expansion, and metabolic phenotype at sequential stages post-implantation by RNA sequencing, histology, and host serology. Expression of metabolic genes is observed at weeks 1-2, followed by the cellular organization into hepatic cords by weeks 4-9.5. Furthermore, grafted engineered tissues exhibited progressive spatially restricted expression of critical functional proteins known to be zonated in the native human liver. This is the first report of engineered human liver tissue zonation after implantation in vivo, which can have important translational implications for this field.

Indexed as

End Stage Liver DiseaseLiver TransplantationOrgan TransplantationHumansTissue EngineeringbioengineeringlivermetabolismRNAseqzonation

Identifiers

PMID36328790
PMCPMC10259871
OpenAlexW4308066056

What OpenQuestion holds

Textmetadata
LicenceCC BY-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.